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Abstract: Objective:There aremany settingsinwhich a spacerdevice is not available for the administrationof bronch-
odilator.Therefore, we testedwhether a paper disposable cup is as effective as a commercially produced spacer to ad-
minister bronchodilator.Methodology:Randomised controlled trial. 50 subjects aged16^50 yearswho hadwheeze and a
greater than10% decrease in FEV1after histamine inhalation test (HIT). Subjects were randomised to either the150ml
paper disposable cup group (CUP) or the commercially produced spacer group (SPACER).Twentyminutes after 400mg
salbutamolwas administered FEV1wasmeasured.The recovery indexmeasured post-bronchodilator FEV1as a percen-
tage of baseline FEV1.Also, analysis ofcovariancetestedwhetherrecoveryof FEV1wasrelatedtothemagnitude ofthe fall
following the HIT. Results:There were no statistically significant differences between CUP and SPACER groups in any
characteristics.There was no difference for the recovery index (t48=1.14, P=0.26).Regression analyses showed that the
relationbetweenthemagnitude ofthe fallin FEV1during theHITandthepercentrecoverywasnotdifferentbetweenthe
CUPand SPACER groups (t=1.2, Po0.23).Conclusions:Apaperdisposable cupwas effective for the reversal ofmild to
moderate bronchoconstriction.Therefore, a paper disposable cup can be used for the first-aidmanagement of asthma
whenthere is concern aboutcross-infection and a commerciallyproduced spacer is not available.r2002 Elsevier Science Ltd.
Allrights reserved.
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The administration of bronchodilator is essential for the
¢rst-aid management of an asthma attack. However,
peoplewho have asthma do not always carry a broncho-
dilator with them and may unnecessarily go without
bronchodilator in such situations. Under these circum-
stances people who have asthma should be encouraged
to use bronchodilator belonging to another person or
available in a ¢rst-aid kit. A number of guidelines recom-
mend the use of a commercially produced spacer device
with a pressurised metered dose inhaler (pMDI) for the
management of an asthma attack (1,2).
Concern has been raised about the theoretical possi-
bility of cross-infection between users of spacers in set-
tings such as schools, universities, sporting clubs and
entertainment venues. The New South Wales Depart-
ment of Health has issued a policy regarding infection
control (3).The policy states that if a spacer is to be usedReceived 20 November 2001, accepted in revised form 29May 2002.
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pasteurisation in a domestic dishwasher or by arrange-
ment with a local hospital. It is unlikely that non-clinical
settings where the ¢rst-aid management of asthma is
provided are equipped, or have sta¡ who are trained
and feel competent, to disinfect spacers appropriately
after use. This concern has the potential to discourage
the use of any bronchodilator other than that belonging
to the person having an asthma attack, which would
mean less than optimal asthma management.
The aim of this study was to test the e¡ectiveness of
using a paper disposable cup as a spacer for the delivery
of bronchodilator.The advantage of using a paper dispo-
sable cup is that it is readily available, inexpensive and,
because it is a single-use device, will eliminate cross-in-
fection. Aprevious studyhas shown equivalence in a clin-
ical setting with children who had moderate-to-severe
bronchoconstriction(4). We conducted a randomised
controlled trial to test the hypothesis, that in adults the
administration of bronchodilator through a paper dispo-
sable cup is just as e¡ective for the reversal of mild-to-
moderate bronchoconstriction as the administration
of bronchodilator through a commercially produced
spacer.
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A total of 50 adult subjects were enrolled.The three cri-
teria for inclusion in this study were (1) any person aged
16 years or older and (2) who had a history of wheeze
and (3)whohad a decrease in FEV1greater than10% after
the histamine inhalation test (HIT)(5). Subjectswhomet
the inclusion criteria were consecutively enrolled into
this study. All subjects gave their consent to be involved
in this study and the Human Ethics Committee of the
University of Sydney approved the protocol.
A self-administered questionnaire was used to collect
data about asthma, medication use, smoking, and demo-
graphics such as age and sex.
Randomisation andmasking
A randomnumber chartwas used to generate an alloca-
tion list. Allocation was concealed within consecutively
numbered sealed envelopes that contained the word
CUP or SPACER. After completion of the HIT, eligible
subjectswererandomly assigned to one of the two treat-
ment groups. An investigator who did not perform the
spirometry determined subject allocation by opening
the next consecutive envelope in the series. Subjects
were then taken to another room to administer the
bronchodilator. Di¡erent investigators performed the
spirometry and the administration of bronchodilator to
ensure that the investigator who performed spirometry
was blinded to group allocation.
CUP group
A150ml paper disposable cup was used and a cross was
cut in the base of the cup.TheVentolin pMDI (100mg sal-
butamol per actuation) was inserted through this open-
ing into the base of the cup. The cup was placed within
5 cm of the front of the subject’s face and the investiga-
tor’s hand was placed over the opening of the cup. The
pMDIwas actuatedonce, the subjectwas told tobreathe
out and then the investigator’s hand was removed from
the opening of the cup and the subject inhaled deeply.
The subject was told to hold their breath for up to 10 s
and then to breathe out. The investigator then moved
the cup to the side of the subject’s face, to ensure that
the subject did not breathe into the cup. A new cupwas
used for each subject.The cycle took approximately15 s
to complete and was repeated four times within a min-
ute.
SPACER group
AVolumatic spacer with aVentolin pMDIwas used in this
arm of the study.The pMDI was actuated once into the
spacer, the subject was told to breathe out and then
place their lips around themouthpiece and then to inhaledeeply. To prevent cross-infection, a small cardboard
mouthpiece was placed over theVolumatic mouthpiece.
The subject was told to hold their breath for up to 10 s
and then breathe out.The cycle took approximately15 s
to complete and was repeated four times within a min-
ute.
Statistical analyses
A recovery index was used as the outcome measure to
determine the e¡ectiveness of the use of a paper dispo-
sable cup as a spacer.The recovery indexmeasuredpost-
bronchodilator FEV1as a percentage of baseline FEV1and
was calculated for each group. The disposable cup was
considered as e¡ective as the spacer if the mean recov-
ery index was within 10% of the spacer. Sample size cal-
culations estimate 28 subjects are needed in each group
for power = 80% and alpha = 0.1when SD is1.5%.
Statistical analyses were performed with the statisti-
cal program SAS (version 6.22, Cary, NC: SAS Institute
Inc).Datawere comparedusingmeanvalues for normally
distributed variables and medians for non-normally dis-
tributed variables. Response dose ratio (RDR) was log-
transformed to test for normality.The CUP and SPACER
groupswere comparedusing a two-sample t-test for nor-
mally distributed variables and a Wilcoxon non-para-
metric test for non-normally distributed variables.
Percent change in FEV1 after bronchodilator was
plotted against per cent change in FEV1 after challenge
and the regression line for each group calculated. Analy-
sis of covariance was used to test for a signi¢cant di¡er-
ence between the regression slopes of the two groups.
RESULTS
A total of 50 subjects took part in this study.There was
no signi¢cant di¡erence in number ofmales, smokers, di-
agnosed asthma, using asthmamedications ormean age,
baseline % predicted FEV1or baseline FEV1between the
CUP and SPACER groups.No subjects were randomised
and then withdrawn from the study due to extreme
breathlessness or wheezing after being givenbronchodi-
lator by eithermethod.
The results following administration of histamine and
bronchodilator are shown inTable1. After histaminewas
administered there was no statistically signi¢cant di¡er-
encebetween groups in themeandecrease in FEV1,med-
ian RDR or the median time between administering
bronchodilator andmeasuring the e¡ecton FEV1. A total
of 64% of subjects in the CUP group and 72% of subjects
in the SPACER group had a decrease in FEV1 of greater
than or equal to 20% after administration of histamine.
After the bronchodilator was administered therewas
no di¡erence in the recovery index, which was used to
determine the e¡ectiveness of each of the methods.
TABLE 1. Characteristics of the CUPand SPACER groups after administration of histamine andbronchodilator
CUPgroup
n= 25
SPACER group
n=25
P value
After administration of histamine
Meandecrease in FEV1 (%) (SD) 20% (6.5) 23% (6.7) 0.14
Median RDR (%fall FEV1/mmol) (IQR) 18.6 (57.3) 15.8 (26.8) 0.56
Mediantime to reversal FEV1 (min) (IQR) 18.0 (12.0) 18.0 (11.0) 0.31
Afteradministration of bronchodilator
Mean Recovery Index (%) (SD) 98% (6) 100% (6) 0.26
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the cup group of baseline and returned to100% of base-
line FEV1 in the SPACER group (P=0.26). The mean and
95% con¢dence interval around the CUP recovery index
was 98% (95% CI 96%, 100%). This result demonstrates
equivalence between the two devices because the upper
and lower limits of the CUP con¢dence interval is within
10% of the SPACER recovery index re£ecting equiva-
lence.
Regression analysis was performed to examine
whether the relation between the percent change in
FEV1after bronchodilator to the percent change in FEV1
after challenge was di¡erent for each of the CUP and
SPACER groups.This analysis showed that the di¡erence
between regression slopes for the CUP and SPACER
group was not statistically signi¢cantly di¡erent
(t=1.2, Po0.23).
DISCUSSION
We found that a disposable paper cup is equally as e¡ec-
tive as a commercially produced spacer for the reversal
of mild-to-moderate bronchoconstriction in adults. The
recovery index showed similar changes after bronchodi-
lator administrationwhether by paper disposable cup or
by a commercially produced spacer.
In this study both selection and observer bias was
minimised. The subjects were reliably randomised to
each of the treatment groups and the study had enrolled
adequate sample size to be able to test for a di¡erence
between groups. No subjects were excluded from the
study because of discomfort or worsening bronchocon-
striction.
We attempted to replicate a‘real life’ situation by using
subjects who had various degrees of bronchoconstric-
tion.We also used the dosage of bronchodilator (400mg
salbutamol) recommended by the National Asthma
Council of Australia and taught in First Aid courses for
the management of asthma. This study complements
other studies by showing that for mild-to-moderate
bronchoconstriction both methods of administrationwere equally e¡ective for reversing bronchoconstric-
tion.
School and sports centre sta¡ and occupational ¢rst
aiders may feel reluctant to administer another person’s
bronchodilator, or to use a communaluse spacerbecause
of government infection control policies. Furthermore,
spacer devices require maintenance that may not occur
in the hands of untrained non-medical personnel. A
study of paediatricians in training demonstrated that
even this group had variable understanding of the use
and maintenance of the spacer device(6). Adults who
have asthmamay themselvesbe reluctant to usebronch-
odilator when they are concerned about the possibility
of becoming infected with a communicable disease.We
do not recommend the use of the disposable paper cup
in settings where adult patients have access to their own
pMDI or to a disinfected commercially produced spacer.
However, in non-clinical settings where there is concern
about theoretical cross-infection, the use of a disposable
paper cup is an e¡ective and hygienic alternative for the
¢rst-aidmanagement of asthma.
The issue of the time course of natural recovery after
theHIT is an important consideration.Cartieretal.mea-
sured the duration of the plateau period, which is the
period immediately after administration of histamine
during which time there is minimal recovery in FEV1 (7).
In their study, inwhich a similar dose of histamine to our
study was used, the plateau period lasted for a mean of
16.8min, range 4^37min. After the plateau period re-
covery proceeded with some subjects requiring 90min
to recover from their bronchospasm. Similarly, a study
of adults reportedbyMatheŁ et al. showed that the induc-
tion of bronchospasmmight last from15 to 30min (8). In
children, Gerritsen et al. showed that natural recovery
time was related to the dose of histamine administered
and the degree of bronchoconstriction caused (9). In
their study, similar to this study in terms of dose of hista-
mine administered and degree of bronchoconstriction
caused, they reported that after 15min only 18% of chil-
dren’s FEV1had recovered towithin 95% of their baseline
level. Furthermore, at 30min post-challenge just over
half of their subjectshadrecovered towithin 95%of their
baseline level. These studies give us con¢dence that in
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of bronchodilator was attributable to the e¡ectiveness
of the devices delivering the bronchodilator and not due
to natural recovery.
The use of a commercially produced spacer device and
pMDIre£ectsbestpractice for the ¢rst-aidmanagement
of asthma andwe do not recommend the use of a dispo-
sablepaper cupwhere one is available.However, concern
is increasing about the risk of infection, and subsequent
litigation, from ¢rst aid provided in non-clinical settings.
This study shows that management guidelines can be
modi¢ed to include the use of a disposable paper cup in
settings where there is concern about cross-infection
and where a casualty does not have their own pMDI or
access to a clean commercially produced spacer device
for the ¢rst aidmanagement of an asthma attack.
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